Adamas Pharmaceuticals Inc Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation
Stock-based compensation
Change in preferred stock warrant value
Accretion of interest expense
Change in fair value of embedded derivative liability
Net accretion of discounts and amortization of premiums of available-for-sale securities
Loss on fixed asset disposal
Loss on disposal of fixed assets
Realized gain on available-for-sale securities
Provision for write-down of inventory
Changes in assets and liabilities
Accrued interest of available-for-sale securities
Accounts receivable, net
Inventory
Prepaid expenses and other assets
Operating lease right-of-use assets
Accounts payable
Current portion of long-term debt
Long-term portion of operating lease liabilities
Accrued liabilities and other liabilities

Net cash used in operating activities
Cash flows from investing activities
Purchases of property and equipment
Purchases of available-for-sale securities
Maturities of available-for-sale securities
Sales of available-for-sale securities
Net cash provided by investing activities
Cash flows from financing activities
Proceeds from public offerings, net of offering costs
Proceeds from issuance of long-term debt
Payment of debt issuance costs
Repurchase of common stock
Proceeds from issuance of common and preferred stock upon exercise of warrants
Proceeds from issuance of common stock upon exercise of stock options
Proceeds from employee stock purchase plan
Net cash provided by financing activities

Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure
Cash paid for income taxes
Cash paid for interest

Supplemental disclosure of noncash activities
Right-of-use assets obtained in exchange for operating lease liabilities
Property and equipment in accounts payable and accrued expense
Stock-based compensation capitalized in inventory
Stock option exercise settled after period end
Property and equipment acquired through tenant improvement allowance

Comments